医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Aroa Biosurgery and Hydrofera Team up in US

2018年05月02日 PM07:00
このエントリーをはてなブックマークに追加


 

MANCHESTER, Conn. & AUCKLAND, New Zealand

New Zealand biomedical company Aroa Biosurgery and United States medical products company Hydrofera are launching Appulse in North America.

The two companies have recently bought back their wound care businesses from Hollister Inc.

Brian Ward, CEO of Aroa Biosurgery, says the company’s Endoform wound care technology and Hydrofera Blue are complementary.

“We have both been successfully represented by Hollister, but with Hollister’s decision to divest portions of its wound care business back to the technology developers, it gives us the opportunity to now grow the businesses ourselves.”

Tom Drury, CEO of Hydrofera, says: “On June 1 we will launch Appulse and most of the Hollister sales team for Endoform and Hydrofera Blue will continue to represent both products.

“This will help ensure the same level of service to patients, clinicians and distribution partners.”

Endoform is a proprietary extracellular matrix (ECM) biomaterial, which contains a collagen scaffold and important secondary molecules to support healing.

Endoform Dermal Template was launched in the US in 2013 for the treatment of acute and chronic wounds after obtaining US Food & Drug Administration (FDA) clearance. Since then Endoform has become established as a leading product for treating diabetic and venous ulcers and been used in more than 2.5 million treatments.

Hydrofera, LLC produces a unique line of antibacterial wound dressings, utilizing its proprietary PVA and polyurethane foam technology in combination with two natural organic pigments. This unique combination of two technology platforms yields a line of advanced wound dressings that improve patient outcomes and lower treatment costs.

About Aroa Biosurgery:
Aroa is a private, venture funded soft-tissue repair company that develops and manufactures medical products to improve healing. Its products are developed from their Endoform™ platform, a novel extracellular matrix biomaterial. The company strives to improve patient outcomes and provide better healing, every day, everywhere for everybody. www.aroabio.com

About Hydrofera, LLC
Hydrofera, LLC, is owned by a group of investors led by Tom Drury, one of the founders of Hydrofera Blue products. The company develops and manufactures Polyvinyl Alcohol (PVA) foam products for medical applications. Headquartered in Manchester, Connecticut, Hydrofera LLC serves customers in the United States and Canada with its award-winning portfolio of Hydrofera Blue products.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180502005672/en/

CONTACT

For information contact:
Aroa Biosurgery Ltd
Brian
Ward, +64 21 727646
brian.ward@aroabio.com
www.arobio.com
or
Hydrofera
LLC
Tom Drury, +1 8609307819
tomd@hyrof.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Celltrion and Teva Announce FDA Approval of HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®, for the Treatment of HER2-Overexpressing Breast Cancer for Certain Indications
  • Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD
  • Tilray®宣布成立国际顾问委员会
  • 武田和纽约科学院宣布2019年度科学创新者奖获奖人
  • AMRA、身体組成の非侵襲的測定を実現する磁気共鳴診断ソフトウエアアプリケーションのAMRA® Profilerで米国FDAの承認を取得